SynthesisZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].
Synthesis in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive type of intestinal T-cell lymphoma. With the application of high-throughput sequencing technologies in recent years, the understanding of this entity has become increasingly comprehensive. The World Health Organization classification of lymphoma now recognizes MEITL as a distinct disease entity. However, the extreme rarity of MEITL poses substantial challenges for clinical diagnosis and management, and patient outcomes remain poor. Based on a systematic review of recent literature, this article summarizes the diagnostic criteria of MEITL, integrating pathology and molecular biology; outlines current multimodal treatment approaches centered on surgery, chemotherapy, and hematopoietic stem cell transplantation; and reviews available clinical and translational data to explore the potential role of epigenetic agents, JAK/STAT pathway inhibitors, and other emerging therapeutic strategies in MEITL. This article summarizes the current status and recent advances in the diagnostic and therapeutic strategies for MEITL in clinical practice and provides a reference for the design of future prospective, multicenter clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.